Dogwood Therapeutics, Inc.

Dogwood Therapeutics is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illness. Dogwood’s lead product, Halneuron, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications. Halneuron is a small molecule that reduces pain transmission…More by blocking Nav 1.7, a sodium channel involved with the initiation and conduction of nerve impulses in the peripheral nervous system.